Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward

Emerging role of novel and traditional biomarkers in the diagnosis and risk stratification of pregnant women with cardiovascular disease (CVD) are needed to raise the standard of care and optimizing management. Biomarkers that reliably distinguish women at high risk for complication would provide a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hasan Ali Farhan, Israa Fadhil Yaseen
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Biomarkers Cardiovascular disease Pregnancy Congenital heart disease Risk stratification Clinical trials Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/69a1f97577ea459180efc6e334359e09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69a1f97577ea459180efc6e334359e09
record_format	dspace
spelling	oai:doaj.org-article:69a1f97577ea459180efc6e334359e092021-11-06T04:37:51ZBiomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward2666-668510.1016/j.ijcchd.2021.100206https://doaj.org/article/69a1f97577ea459180efc6e334359e092021-10-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666668521001300https://doaj.org/toc/2666-6685Emerging role of novel and traditional biomarkers in the diagnosis and risk stratification of pregnant women with cardiovascular disease (CVD) are needed to raise the standard of care and optimizing management. Biomarkers that reliably distinguish women at high risk for complication would provide a novel biomarker-guided management approach and risk stratification strategy. The role of cardiac biomarkers during pregnancy remain a topic of interest and still need significant investigation with large sample size study. In the clinical trials and researches, pregnant women are usually excluded to avoid adverse effects of the studied medications on the health of these patients and their fetuses. Currently we are in the era of moving toward prevention of CVD more than focusing on the management of established events. Biomarkers can be used to predict the new incidence of CVD or to predict the outcomes of the previously established cardiac events. Depend on such data, enrollment of pregnant women in clinical trials and researches can be encouraged to identify biomarkers profile associated with different CVD to be used in risk stratification for future prevention of such events during pregnancy. In this article we will review some of the evidence about role of biomarkers in pregnant patients with CVD for risk stratification.Hasan Ali FarhanIsraa Fadhil YaseenElsevierarticleBiomarkersCardiovascular diseasePregnancyCongenital heart diseaseRisk stratificationClinical trialsDiseases of the circulatory (Cardiovascular) systemRC666-701ENInternational Journal of Cardiology Congenital Heart Disease, Vol 5, Iss , Pp 100206- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biomarkers Cardiovascular disease Pregnancy Congenital heart disease Risk stratification Clinical trials Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Biomarkers Cardiovascular disease Pregnancy Congenital heart disease Risk stratification Clinical trials Diseases of the circulatory (Cardiovascular) system RC666-701 Hasan Ali Farhan Israa Fadhil Yaseen Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
description	Emerging role of novel and traditional biomarkers in the diagnosis and risk stratification of pregnant women with cardiovascular disease (CVD) are needed to raise the standard of care and optimizing management. Biomarkers that reliably distinguish women at high risk for complication would provide a novel biomarker-guided management approach and risk stratification strategy. The role of cardiac biomarkers during pregnancy remain a topic of interest and still need significant investigation with large sample size study. In the clinical trials and researches, pregnant women are usually excluded to avoid adverse effects of the studied medications on the health of these patients and their fetuses. Currently we are in the era of moving toward prevention of CVD more than focusing on the management of established events. Biomarkers can be used to predict the new incidence of CVD or to predict the outcomes of the previously established cardiac events. Depend on such data, enrollment of pregnant women in clinical trials and researches can be encouraged to identify biomarkers profile associated with different CVD to be used in risk stratification for future prevention of such events during pregnancy. In this article we will review some of the evidence about role of biomarkers in pregnant patients with CVD for risk stratification.
format	article
author	Hasan Ali Farhan Israa Fadhil Yaseen
author_facet	Hasan Ali Farhan Israa Fadhil Yaseen
author_sort	Hasan Ali Farhan
title	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
title_short	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
title_full	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
title_fullStr	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
title_full_unstemmed	Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward
title_sort	biomarker profile and risk stratification in cardiovascular disease during pregnancy: action to move forward
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/69a1f97577ea459180efc6e334359e09
work_keys_str_mv	AT hasanalifarhan biomarkerprofileandriskstratificationincardiovasculardiseaseduringpregnancyactiontomoveforward AT israafadhilyaseen biomarkerprofileandriskstratificationincardiovasculardiseaseduringpregnancyactiontomoveforward
_version_	1718443857304092672

Biomarker profile and risk stratification in cardiovascular disease during pregnancy: Action to move forward

Ejemplares similares